Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

AVEO PHA Form 4 March 29, 2	RMACEUTIC	ALS INC										
										OMB APPROVAL		
Check this box if no longer subject to Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB Number: 3235-02 Statement of the section 16. Statement of the section 16.									3235-0287			
								•				
(Print or Type	Responses)											
BASKETT FOREST S			2. Issuer Name and Ticker or Trading Symbol AVEO PHARMACEUTICALS INC [AVEO]				Ι	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) 1954 GREE DRIVE, SU		(Middle)	3. Date of Earli (Month/Day/Ye 03/28/2017		ansaction		 - b	Director Officer (give ti below)	X10% itleOthe below)			
			4. If Amendmen Filed(Month/Day	onth/Day/Year) Applicable Lin _X_Form file Form file					· Joint/Group Filing(Check by One Reporting Person y More than One Reporting			
(City)	(State)	(Zip)						Person				
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year	te 2A. Deen	ned 3. n Date, if Trans Code	saction e r. 8)		Acquir of (D)	ed (A) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	or Beneficiall 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	03/28/2017		P <u>(1)</u>		6,000,000	А	\$ 0.5	16,362,694	Ι	See Note 2 (2)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Under Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

۲

Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Othe			
BASKETT FOREST 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM, MD 21093		Х					
Signatures							
/s/ Sasha Keough, attorney-in-fact	03/29/2017						

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reports the purchase of shares in the underwritten public offering of common stock of AVEO Pharmaceuticals, Inc.

Date

The Reporting Person is a manager of NEA 15 GP, LLC, ("NEA 15 GP") which is the sole general partner of NEA Partners 15, L.P. ("NEA Partners 15"). NEA Partners 15 is the sole general partner of New Enterprise Associates 15, L. P. ("NEA 15"). NEA 15 is the sole

(2) member of Growth Equity Opportunities Fund IV, LLC ("GEO IV"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by GEO IV in which the Reporting Person has no pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.